For in vivo application toward metastasis treatment, the SEE platform was applied for remodeling AG cells from lung cancer patients by transfecting immunotherapy promoters, Interferon‐γ (IFN‐γ) plasmid, and Programmed cell death ligand 1(PD‐L1) siRNA. The gene discussed is IFNG; the disease is lung carcinoma.